个人简介

  朱波，教授、博士生导师、主任医师，现任陆军军医大学第二附属医院肿瘤科主任。任中华医学会肿瘤学分会常委、中央军委保健委员会第四届会诊专家、中国临床肿瘤学会患者教育专家委员会主任委员。围绕“肿瘤免疫调控细胞分子机制与精准免疫治疗”基础-转化和临床研究方向开展研究工作。先后主持国家杰出青年科学基金、国家自然科学基金国际（地区）合作与交流项目和国家自然科学基金重点项目等23项。在Nat Med、Cancer cell、Sci Trans Med等国际期刊发表论文100余篇，其中IF>10论文25篇。主编/参编专著3部，临床指南11部。获国家自然科学二等奖、重庆市自然科学一等奖、重庆市科进步二等奖、中华医学科技进步一等奖和教育部自然科学二等奖各一项。

教育背景及工作经历

1992.09-1997.07 第三军医大学临床医学学士学位

1997.09-2000.07 第三军医大学实验血液学硕士学位

2000.09-2003.07 第三军医大学肿瘤学博士学位

2003.07-2005.07 第三军医大学第二附属医院主治医师，讲师

2005.07-2007.12 英国伦敦大学Queen Mary医学院，博士后

2005.07-2008.12 第三军医大学第二附属医院副教授，副主任医师

2008.12-2012.06 第三军医大学第二附属医院副主任，教授，博导

2012.06-至今 陆军军医大学第二附属医院主任，教授，博导

科研项目

1. 国家杰出青年科学基金 400万 2020.01-2024.12

2. 国家自然科学基金重点项目 261万 2023.01-2027.12

3. 重庆市2023年度技术创新与应用发展重大专项 1000万 2023.12.10-2026.12.9

代表性论文

1. Cheng X, Wang H, Wang Z, Zhu B*, Long H*. Tumor-associated myeloid cells in cancer immunotherapy. J Hematol Oncol. 2023 Jul 6;16(1):71.  IF= 28.5 综述 一区

2. Xinxin Wang#, Haoran Zha#, Wei Wu, Ting Yuan, Shuanglong Xie, Zheng Jin, Haixia Long, Fei Yang, Zhongyu Wang, Anmei Zhang, Jianbao Gao, Ying Jiang, Lujing Wang, Chunyan Hu, Yisong Y. Wan, Qi-Jing Li, Alistair L.J. Symonds, Qingzhu Jia*, Bo Zhu*. CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. Sci Transl Med. 2023 Jan 18;15(679):eabn5029. IF=19.319 共通  论著 一区 接收

3. Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. Cancer Cell. 2022 May 16:S1535-6108(22)00211-2. IF: 38.585 共通 论著 一区 PMID: 35594863

4. Jia Q, Chu H, Jin Z, Long H*, Zhu B*. High-throughput single-сell sequencing in cancer research. Signal Transduct Target Ther. 2022，7(1):145 IF: 38.104 共通  综述 一区 PMID: 35504878

5. Luo Z, Yao X, Li M, Fang D, Fei Y, Cheng Z, Xu Y*, Zhu B*. Modulating tumor physical microenvironment for fueling CAR-T cell therapy. Adv Drug Deliv Rev. 2022,185:114301 IF:17.873 共通  综述 一区 PMID: 35439570

6. Jia Q, Chiu L, Wu S, Bai J, Peng L, Zheng L, Zang R, Li X, Yuan B, Gao Y, Wu D, Li X, Sun J*, He L, Robinson B, Zhu B*. Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing During Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer. Adv Sci. 2020.7(9):1903410. IF: 17.521

7. Wang Z, Jia Q, Tang X, Yan L, Zhu B*. Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC. J Thorac Oncol.2020,15(1):e1-e3. IF: 20.121

8. Chen X#, Cao G#, Wu J#, Wang X#, Pan Z, Gao J, Tian Q, Xu L, Li Z, Hao Y, Huang Q, Wang P, Xiao M, Xie L, Tang S, Liu Z, Hu L, Tang J, He R, Wang L, Zhou X, Wu Y, Chen M, Sun B, Zhu B*, Huang J*, Ye L*. The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection. Cell Mol Immunol. 2020,17(3):247-260. IF: 22.096

9. Gong Z#; Jia Q#; Chen J; Diao X; Gao J; Wang X; Zhu B*. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients with Lung Adenocarcinoma, J Thorac Oncol,2019, 14（5）：857-866 IF: 20.121

10. Zhou J#, Huang S#, Wang Z#, Huang J, Xu L, Tang X, Wan YY, Li QJ, Symonds ALJ, Long H*, Zhu B*.Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. Nat Commun. 2019,10(1):2427. IF: 17.694

11. Zhao L#; He R#; Long H#; Guo B#; Jia Q; Qin D; Liu SQ; Wang Z; Xiang T; Zhang J; Tan Y; Huang J; Chen J; Wang F; Xiao M; Gao J; Yang X; Zeng H; Wang X; Hu C; Alexander PB; Symonds ALJ; Yu J; Wan Y; Li QJ*; Ye L* Zhu B*. Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells., Nat Med,2018,24(10): 1536~1544. IF: 87.241

12. Jia Q#; Wu W#; Wang Y; Alexander PB; Sun C; Gong Z; Cheng JN; Sun H; Guan Y; Xia X; Yang L; Yi X; Wan YY; Wang H; He J; Futreal PA; Li QJ*, Zhu B*. \Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun,2018,9(1): 5361. IF: 17.694

13. Liu J(#); Tan Y(#); Zhang J(#); Zou L; Deng G; Xu X; Wang F; Ma Z; Zhang J; Zhao T; Liu Y; Li Y; Zhu B(*); Guo B(*), C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis, J Hepatol,2015,62(2): 354~362  30.083